Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

1. Age 18-75 years old, gender unlimited

2. Esophageal squamous cell carcinoma confirmed by histology and unresectable locallyadvanced or postoperative recurrence

3. According to the solid tumor efficacy evaluation criteria (RECIST1.1), there is atleast one measurable lesion; And the lesion had not received prior radiotherapy

4. ECOG: 0~1

5. Expected survival ≥12 weeks 6. Laboratory examination: neutrophils ≥1.5 x 109/L,platelets ≥100 x 109/L; Hemoglobin ≥ 9g/L; Albumin ≥ 2.8g/dL; Bilirubin ≤1.5 timesULN, ALT and AST≤2.5 times ULN

7: Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up 8: Tissue samples should be provided for biomarker analysis such as (PD-L1). Newly acquired tissues are preferred, and 15 5-6um thick paraffin sections can not be provided for archiving by the recent organizer

Exclusion Criteria:

1. Other malignant tumors have been diagnosed within the previous 5 years

2. There is distant organ metastasis (according to AJCC stage, supraclavicular lymphnode metastasis is M1, which should be excluded)

3. Lesions invading the trachea or large blood vessels, or investigators judge thatthere is a high risk of esophageal/tracheal fistula or bleeding

4. Have any history of active autoimmune disease or autoimmune disease

5. Have clinical symptoms or diseases of the heart that are not under control

6. Active infection or fever (except definite tumor fever)

7. History or evidence of interstitial lung disease or active non-infectious pneumonia

8. Patients with immune dysfunction and active hepatitis

9. Those who have previously received PD-1 or PD-L1 antibody therapy

10. Allergic to any drug in this protocol

11. Patients receiving immunosuppressive drugs or corticosteroids >10mg/ day ofprednisone therapeutic dose within 14 days prior to enrollment

12. Patients who had received radiotherapy, chemotherapy, targeted therapy, orimmunotherapy within 4 weeks prior to enrollment

13. Pregnant or lactating women